Overview

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the safety and tolerability of EC-MPS in maintenance renal transplant patients who experience gastrointestinal (GI) intolerance due to adverse events associated with mycophenolate mofetil (MMF) and were converted to EC-MPS.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Treatments:
Mycophenolate mofetil
Mycophenolic Acid